Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomics and HCV infection: progression of fibrosis and treatment response.

Journal of hepatology - 1 Nov 2012

Estrabaud Emilie, Vidaud Michel, Marcellin Patrick, Asselah Tarik

Abstract excerpt

HCV infection is a global health problem that affects 170 million people worldwide. The severity of the disease varies from asymptomatic chronic infection to cirrhosis and hepatocellular carcinoma (HCC). Recently, the standard of care for genotype 1 patients has greatly improved with the addition of protease inhibitors (telaprevir or boceprevir) to pegylated interferon (PegIFN) and ribavirin (RBV). The prediction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Disease Progression
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Liver Cirrhosis

Share to Pharmacogenetics

Source

Identifiers

PMID: 22659520
DOI: 10.1016/j.jhep.2012.05.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomics and HCV infection: progression of fibrosis and treatment response.PMID 22659520Read ↗

Host genomics and HCV treatment response.Semantic proximity Read ↗

Host genomics and HCV personalized medicine.Semantic proximity Read ↗

Novel findings for the development of drug therapy for various liver diseases: Genetic variation in IL-28B is associated with response to the therapy for chronic hepatitis C.Semantic proximity Read ↗

Genetics, Genomics, and Proteomics: Implications for the Diagnosis and the Treatment of Chronic Hepatitis CSemantic proximity Read ↗

Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.Semantic proximity Read ↗

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Semantic proximity Read ↗

Natural history and clinical response: "it's the virus, stupid, or is it the host?".Semantic proximity Read ↗

IL28B polymorphism and genetic biomarkers of viral clearance in hepatitis C virus infection.Semantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.Semantic proximity Read ↗

Correlation between genetic variations and serum level of interleukin 28B with virus genotypes and disease progression in chronic hepatitis C virus infection.Semantic proximity Read ↗

Genetics of IL28B and HCV--response to infection and treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.